专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240033258A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS 审中-公开
公开(公告)号：US20240033258A1
公开(公告)日：2024-02-01
申请号：US18374860
申请日：2023-09-29
申请人： Board of Supervisors of Louisiana State University & Agricultural & Mechanical College
发明人： Nicholas E. Goeders
IPC分类号： A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/5513 , A61K45/06 , A61K31/195 , A61K31/42 , A61K31/519 , A61K31/55 , A61K31/5517
CPC分类号： A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/5513 , A61K45/06 , A61K31/195 , A61K31/42 , A61K31/519 , A61K31/55 , A61K31/5517
摘要： The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.

2. 发明授权

US09987286B2 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease 有权
公开(公告)号：US09987286B2
公开(公告)日：2018-06-05
申请号：US14736619
申请日：2015-06-11
申请人： Embera NeuroTherapeutics, Inc. , Board of Supervisors of Louisiana State University & Agricultural & Mechanical College
发明人： Nicholas E. Goeders , Barbara S. Fox , Glenn Guerin
IPC分类号： A61K31/445 , A61K31/5513 , A61K31/55 , A61K31/444 , A61K31/496 , A61K45/06
CPC分类号： A61K31/5513 , A61K31/444 , A61K31/496 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.

3. 发明申请

US20160346261A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS 审中-公开
公开(公告)号：US20160346261A1
公开(公告)日：2016-12-01
申请号：US15235947
申请日：2016-08-12
申请人： Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College
发明人： Nicholas E. Goeders
IPC分类号： A61K31/444 , A61K31/195 , A61K31/519 , A61K31/5517 , A61K31/496 , A61K31/42 , A61K31/55 , A61K31/5513
CPC分类号： A61K31/444 , A61K31/195 , A61K31/42 , A61K31/496 , A61K31/4985 , A61K31/519 , A61K31/55 , A61K31/5513 , A61K31/5517 , A61K45/06
摘要： The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.

4. 发明授权

US09415107B2 Compositions and methods for the treatment of addiction and other neuropsychiatric disorders 有权
标题翻译：用于治疗成瘾和其他神经精神障碍的组合物和方法
公开(公告)号：US09415107B2
公开(公告)日：2016-08-16
申请号：US12093048
申请日：2006-11-13
申请人： Nicholas E. Goeders
发明人： Nicholas E. Goeders
IPC分类号： A01N43/00 , A61K31/33 , A61K45/06 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/5513
CPC分类号： A61K31/444 , A61K31/195 , A61K31/42 , A61K31/496 , A61K31/4985 , A61K31/519 , A61K31/55 , A61K31/5513 , A61K31/5517 , A61K45/06
摘要： The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.
摘要翻译：本发明部分地基于我们的发现，某些类型的治疗剂可以组合使用以治疗各种神经精神和相关疾病，包括成瘾（例如，物质或活性）以及减轻更年期或与月经周期相关的一些症状。不管精确的制剂，本发明的组合物可以包括至少一种靶向下丘脑 - 垂体 - 肾上腺（HPA）轴的活性成分和至少一种靶向前额叶皮层的活性成分。这些类型的试剂中的任一种或两者可以与抑制交感神经系统活性的试剂组合。因此，组合物或组合药物疗法还可以包括抑制β-肾上腺素能受体或以其它方式起抗高血压或抗焦虑药作用的药剂。

5. 发明申请

US20190231902A1 METHOD FOR DELIVERING RNA TO NEURONS TO TREAT HERPES INFECTIONS 审中-公开
公开(公告)号：US20190231902A1
公开(公告)日：2019-08-01
申请号：US16312277
申请日：2017-06-21
申请人： University of Florida Research Foundation, Incorporated , Board of Supervisors of Louisiana State University & Agricultural & Mechanical College
发明人： David C. Bloom , Alfred S. Lewin , Donna M. Neumann , Zachary L. Watson , Sonal Sanjeev Tuli , Gregory Scott Schultz
IPC分类号： A61K48/00 , C12N5/0793 , C12N15/86 , C12N15/113 , A61P31/22
CPC分类号： A61K48/0091 , A61P31/22 , C12N5/062 , C12N15/1133 , C12N15/86 , C12N2310/121 , C12N2310/20 , C12N2320/32 , C12N2510/00 , C12N2750/14122 , C12N2750/14143 , C12N2750/14145
摘要： Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.

6. 发明授权

US5114863A Immunosorbant assay for .alpha.-1-antitrypsin, kit employing said assay, monoclonal antibody to .alpha.-1-antitrypsin, and hybridoma for producing said monoclonal antibody 失效
标题翻译： α-1-抗胰蛋白酶的免疫吸附试验，使用所述测定的试剂盒，α-1-抗胰蛋白酶的单克隆抗体和用于产生所述单克隆抗体的杂交瘤
公开(公告)号：US5114863A
公开(公告)日：1992-05-19
申请号：US617402
申请日：1990-11-15
申请人： Candace C. McCombs , Joseph P. Michalski , William R. Gallaher , James J. Thompson
发明人： Candace C. McCombs , Joseph P. Michalski , William R. Gallaher , James J. Thompson
IPC分类号： C07K16/38 , G01N33/573
CPC分类号： G01N33/573 , C07K16/38 , Y10S435/97 , Y10S436/805 , Y10S436/81
摘要： A double antibody sandwich immunosorbent assay for detecting alpha-1-antitrypsin (.alpha..sub.1 AT) comprising the steps of: (1) reacting (a) a first-species-of-animal antibody to .alpha..sub.1 AT with (b) a solid substrate; (2) reacting (a) .alpha..sub.1 AT in a sample suspected of containing .alpha..sub.1 AT with (b) the first-species-of animal polyclonal antibody to .alpha..sub.1 AT; (3) reacting (a) a second-species-of-animal antibody to .alpha..sub.1 AT with (b) the .alpha..sub.1 AT in a sample suspected of containing .alpha..sub.1 AT; (4) reacting (a) a labelled antibody comprising a first-species-of-animal antibody to an antibody from a second species of animal with (b) the second-species-of-animal antibody to .alpha..sub.1 AT; and (5) detecting the amount of labelled first-species-of-animal antibody to antibody from the second species of animal that reacted with the second-species-of-animal polyclonal antibody to .alpha..sub.1 AT; provided that the first species of animal and the second species of animal are not the same in a given assay; and provided that steps (1) to (4) can be conducted in any order so as to result in a complex comprising: (i) the substrate complexed to (ii) the first-species-of-animal antibody to .alpha..sub.1 AT complexed to (iii) the .alpha..sub.1 AT complexed to (iv) the second-species-of-animal antibody to .alpha..sub.1 AT complexed to (v) the labelled antibody. The antibodies used in the assay can be polyclonal antibodies or monoclonal antibodies. A kit for detecting .alpha..sub.1 AT comprising reagents for conducting the above described assays. A monoclonal antibody having specific reactivity to .alpha..sub.1 AT, the antibody being further characterized in that it exhibits substantially no cross reactivity with albumin. A hybridoma that produces the above described monoclonal antibody.
摘要翻译：用于检测α-1-抗胰蛋白酶（α1AT）的双抗体夹心免疫吸附测定法，包括以下步骤：（1）使（a）第一种动物抗体与α1AT与（b）固体底物反应; （2）将疑似含有α1AT的样品中的（a）α1AT与（b）第一种动物多克隆抗体与α1AT反应; （3）将（a）第二种动物抗体与α1AT与（b）在怀疑含有α1AT的样品中的α1AT反应; （4）使（a）包含第一种动物抗体的标记抗体与来自第二种动物的抗体与（b）第二种动物抗体α1AT反应; 和（5）检测来自与第二种动物多克隆抗体与α1AT反应的动物的第二种动物的抗体的标记的第一种动物抗体的量; 前提是第一种动物和第二种动物在给定的测定中不相同; 并且条件是步骤（1）至（4）可以以任何顺序进行，以便产生复合物，其包含：（i）与（ii）与α1AT复合的第一种动物抗体复合的底物（iii）与（iv）与（v）标记抗体复合的α1AT的第二种动物抗体复合的α1AT。测定中使用的抗体可以是多克隆抗体或单克隆抗体。用于检测α1AT的试剂盒，其包含用于进行上述测定的试剂。具有与α1AT具有特异性反应性的单克隆抗体，该抗体的进一步特征在于它表现出与白蛋白基本上没有交叉反应性。产生上述单克隆抗体的杂交瘤。

7. 发明申请

US20220380808A1 METHOD FOR DELIVERING RNA TO NEURONS TO TREAT HERPES INFECTIONS 有权
公开(公告)号：US20220380808A1
公开(公告)日：2022-12-01
申请号：US17738987
申请日：2022-05-06
申请人： University of Florida Research Foundation, Incorporated , Board of Supervisors of Louisiana State University & Agricultural & Mechanical College
发明人： David C. Bloom , Alfred S. Lewin , Donna M. Newmann , Zachary L. Watson , Sonal Sanjeev Tuli , Gregory Scott Schultz
IPC分类号： C12N15/861 , A61P31/22
摘要： Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.

8. 发明申请

US20220202791A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS 有权
公开(公告)号：US20220202791A1
公开(公告)日：2022-06-30
申请号：US17396951
申请日：2021-08-09
申请人： Board of Supervisors of Louisiana State University & Agricultural & Mechanical College
发明人： Nicholas E. Goeders
IPC分类号： A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/5513 , A61K45/06 , A61K31/195 , A61K31/42 , A61K31/519 , A61K31/55 , A61K31/5517
摘要： The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.

9. 发明授权

US11351273B2 Method for delivering RNA to neurons to treat herpes infections 有权
公开(公告)号：US11351273B2
公开(公告)日：2022-06-07
申请号：US16312277
申请日：2017-06-21
申请人： University of Florida Research Foundation, Incorporated , Board of Supervisors Of Louisiana State University & Agricultural & Mechanical College
发明人： David C. Bloom , Alfred S. Lewin , Donna M. Neumann , Zachary L. Watson , Sonal Sanjeev Tuli , Gregory Scott Schultz
IPC分类号： C07H21/04 , A61K48/00 , C12N15/113 , C12N15/86 , A61P31/22 , C12N5/0793
摘要： Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.

10. 发明申请

US20160374962A1 MICROSIZED CURCUMIN COMPOSITIONS 审中-公开
标题翻译：微量的曲霉组合物
公开(公告)号：US20160374962A1
公开(公告)日：2016-12-29
申请号：US15260275
申请日：2016-09-08
申请人： THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGE
发明人： Cherie-Ann Nathan
IPC分类号： A61K31/12 , A61K9/00 , A61K9/16 , A61K31/455
CPC分类号： A61K31/12 , A61K9/0056 , A61K9/0058 , A61K9/006 , A61K9/06 , A61K9/16 , A61K31/455 , A61K31/465 , A61K2300/00
摘要： Disclosed herein are formulations for the local delivery of therapeutically effective doses of curcumin that provide sufficient serum levels of curcumin to treat diseases such as head and neck disorders and upper aerodigestive disorders.
摘要翻译：本文公开了用于局部递送治疗有效剂量的姜黄素的制剂，其提供足够的血清水平的姜黄素以治疗诸如头颈部疾病和上消化道疾病的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式